Deadline: 15 March 2025
The AIM-HI Women’s Venture Competition 2025 is now open to women-led oncology companies worldwide!
This competition comprised of three parts: general information, a presentation summarizing a business plan, and a brief video delivered in easy-to-understand language for a general audience.
Funding Information
- An Investment Committee will conduct detailed due diligence research on the finalists to determine whether an investment will be made based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will receive up to $1 million in investment from AIM-HI and co-investors.
Eligibility Criteria
- Women-led oncology companies seeking pre-seed, seed, and Series A investments are eligible to apply.
- The company must have a woman in senior leadership, who has an equity stake – could be Founder or C-level executive.
- The applying company must have technology ownership in place.
Selection Process
- Their three-part Selection, Judging, and Investment Committees consist of world-class life sciences industry professionals, business leaders, and investors.
- All submitted applications will be reviewed and screened by their Selection Committee based on the quality of applications. 6-8 semi-finalists will be chosen around late April and invited to compete in front of a Judging Committee in June to select finalists who will be recognized and awarded honorariums and certificates.
For more information, visit AIM-HI Accelerator Fund.
